Further to the above. This is analysis of data from another...

Further to the above. This is analysis of data from another paper published in 1982.

@Mason14's punch line from Post #:54368862

The following paper I discuss is a phase I study investigating the safety, tolerability, and clinical efficacy of Bisantrene (1). At the time, the authors were also undertaking an in vitro (cellular) study investigating the sensitivity of Bisantrene in human tumor samples. The authors found that Bisantrene was able to reduce survival of tumor colony-forming units (basically growth) by at least 62% in some samples at concentrations of 0.1 - 1.0 ug/mL over an hour of exposure. The authors comment that this concentration of Bisantrene is 2-20% of the plasma concentration achieved from a 260 mg/m2 dose of Bisantrene, which works out to be 5.2 - 52 mg/m2 (theorised FTO inhibitory dose ~ 7.5 mg/m2). Put simply, the concentration required to inhibit the growth of cancer in vitro is around the concentration theorised for Bisantrene to function as an FTO inhibitor in humans.